机译:用同种异体造血细胞移植治疗(HCT)对急性髓性白血病(AML)的患者(PTS)中的存活差异与非HCT疗法:大型实时多中心前瞻性纵向观察研究
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Univ Washington Sch Publ Hlth Dept Biostat Seattle WA 98195 USA;
Cleveland Clin Leukemia &
Myeloid Disorders Program Cleveland OH 44106 USA;
Stanford Univ Dept Med Div Hematol Palo Alto CA 94304 USA;
Univ Utah Huntsman Canc Inst Salt Lake City UT USA;
Northwestern Univ Feinberg Sch Med Chicago IL 60611 USA;
Northwestern Univ Robert H Lurie Comprehens Canc Ctr Feinberg Sch Med Chicago IL 60611 USA;
Univ Penn Sch Med Abramson Canc Ctr Philadelphia PA 19104 USA;
Univ Maryland Greenebaum Comprehens Canc Ctr Baltimore MD 21201 USA;
Duke Univ Sch Med Div Hematol Malignancies &
Cellular Therapy Durham NC USA;
Washington Univ Sch Med Div Oncol St Louis MO USA;
Roswell Pk Comprehens Canc Ctr Leukemia Serv Buffalo NY USA;
Hackensack Univ Med Ctr John Theurer Canc Ctr Hackensack NJ USA;
Hackensack Univ Med Ctr John Theurer Canc Ctr Hackensack NJ USA;
Cleveland Clin Leukemia &
Myeloid Disorders Program Cleveland OH 44106 USA;
Cleveland Clin Leukemia &
Myeloid Disorders Program Cleveland OH 44106 USA;
Wenatchee Valley Hosp Confluence Health Wenatchee WA USA;
Wenatchee Valley Hosp Confluence Health Wenatchee WA USA;
Skagit Valley Hosp Reg Canc Care Ctr Mt Vernon IA USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
Fred Hutchinson Canc Res Ctr Clin Res Div 1124 Columbia St Seattle WA 98104 USA;
机译:用同种异体造血细胞移植治疗(HCT)对急性髓性白血病(AML)的患者(PTS)中的存活差异与非HCT疗法:大型实时多中心前瞻性纵向观察研究
机译:Thiotepa-Fludarabine-Treosulfan(TFT)用于第二种异种外周血造血细胞移植(HCT)的调节来自急性髓性白血病(AML)的第二个无关助剂(AML)后复发,后两项基因HCT:预期多中心第二期试验
机译:接受对同种异体造血细胞移植治疗急性髓性白血病的限制:大型多中心前瞻性纵向观察研究
机译:同种异体造血细胞移植(HCT)中抑制杀伤细胞IG样受体(IKIR)匹配的影响
机译:根据2017年日本成人白血病研究组(JALSG)AML201研究治疗的成人急性髓性白血病患者的遗传学预测,根据2017 ELN风险分层进行预后分析
机译:早期或晚期先发性异基因造血细胞移植(p-alloHCT)用于复发性或难治性急性髓系白血病(AML)
机译:接受对同种异体造血细胞移植治疗急性髓性白血病的限制:大型多中心前瞻性纵向观察研究